12-hydroxy stearic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
12-hydroxyoctadecanoic acid : A hydroxy fatty acid that is stearic acid bearing a hydroxy substituent at position 12. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 7789 |
| CHEMBL ID | 292352 |
| CHEBI ID | 85208 |
| SCHEMBL ID | 17773 |
| MeSH ID | M0534053 |
| Synonym |
|---|
| stearic acid, 12-hydroxy- |
| 12-hydroxystearic acid |
| nsc-2385 |
| nsc2385 |
| cerit fac 3 |
| hydrofol acid 200 |
| octadecanoic acid, 12-hydroxy- |
| 12-hydroxyoctadecanoic acid |
| 106-14-9 |
| wln: qv10yq6 |
| inchi=1/c18h36o3/c1-2-3-4-11-14-17(19)15-12-9-7-5-6-8-10-13-16-18(20)21/h17,19h,2-16h2,1h3,(h,20,21 |
| 12-hydroxyoctadecanoic acid, 99% |
| NCGC00164350-01 |
| ai3-19730 |
| brn 1726730 |
| ceroxin gl |
| hydroxystearic acid |
| einecs 253-004-1 |
| loxiol g 21 |
| hsdb 5368 |
| KOW , |
| nsc 2385 |
| dl-12-hydroxystearic acid |
| barolub fto |
| einecs 203-366-1 |
| CHEMBL292352 |
| 12-hydroxy-octadecanoic acid |
| chebi:85208 , |
| H0308 |
| 8039-23-4 |
| NCGC00164350-02 |
| LMFA02000130 |
| dl-12-hydroxy stearic acid |
| NCGC00257021-01 |
| dtxcid606725 |
| dtxsid8026725 , |
| tox21_303035 |
| cas-106-14-9 |
| NCGC00259043-01 |
| tox21_201492 |
| 27924-99-8 |
| einecs 227-283-5 |
| 12-hydroxystearic acid estolide |
| yxh47aou0f , |
| unii-yxh47aou0f |
| AKOS016010128 |
| einecs 242-295-0 |
| 933anu3h2s , |
| ec 203-366-1 |
| 4-03-00-00942 (beilstein handbook reference) |
| unii-933anu3h2s |
| FT-0607234 |
| dl-12-hydroxyoctadecanoic acid |
| hydroxystearic acid [inci] |
| 12-hydroxyoctadecanoic acid [hsdb] |
| 12-hydroxystearic acid [usp-rs] |
| casid hsa |
| 12-hydroxy-stearic acid |
| 12-hydroxy stearic acid |
| SCHEMBL17773 |
| 36377-33-0 |
| W-110875 |
| W-108773 |
| mfcd00004592 |
| (?)-12-hydroxyoctadecanoic acid |
| 12-hydroxystearic acid, united states pharmacopeia (usp) reference standard |
| 78642-86-1 |
| 12-hydroxyoctadecanoicacid |
| Q27158401 |
| benzyl(2s,3as,7as)-octahydro-1h-indole-2-carboxylate4-methylbenezenesulfonate |
| MS-24336 |
| HY-W127329 |
| CS-0185570 |
| E82291 |
| octadecanoic acid, 12-hydroxy-, (a+/-)- |
| PD150654 |
| 12-hydroxystearic acid (usp-rs) |
| Excerpt | Reference | Relevance |
|---|---|---|
| "A majority of studies involving prodrugs are directed to overcome low bioavailability of the parent drug." | ( Targeted lipid based drug conjugates: a novel strategy for drug delivery. Earla, R; Kwatra, D; Mitra, AK; Pal, D; Samanta, SK; Vadlapatla, RK; Vadlapudi, AD, 2012) | 0.38 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| bacterial xenobiotic metabolite | Any bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| hydroxyoctadecanoic acid | A hydroxy fatty acid that is ocatadecanoic acid (stearic acid) in which the aliphatic chain has been substituted by one or more hydroxy groups. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 46.1247 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 51.8714 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 51.8714 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 17.4634 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 7.6959 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 43.2771 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 54.4827 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 22.1311 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 32.6982 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 48.1611 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 68.7989 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 22.8428 | 0.0002 | 29.3054 | 16,493.5996 | AID1259383; AID743069; AID743075 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 19.7135 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 27.7738 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 37.2730 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223 |
| caspase-3 | Homo sapiens (human) | Potency | 43.2771 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 68.5896 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 21.6184 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 6.6422 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 22.5843 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 13.6854 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 31.6228 | 0.0158 | 23.5273 | 44.6684 | AID651778 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Free fatty acid receptor 4 | Homo sapiens (human) | EC50 (µMol) | 1.7378 | 0.0437 | 2.3547 | 7.5858 | AID1416220 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1416220 | Agonist activity at N-terminal FLAG-tagged/C-terminal eYFP-fused human FFA4 receptor expressed in HEK293T cells assessed as induction of beta-arrestin-2 recruitment after 5 mins by BRET assay | 2017 | MedChemComm, Jun-01, Volume: 8, Issue:6 | Succinct synthesis of saturated hydroxy fatty acids and |
| AID167832 | In vitro inhibitory concentration measured against U-46,619 (1 uM) induced aggregation of washed platelets (WP) in rabbit; N-Negative | 1991 | Journal of medicinal chemistry, Jun, Volume: 34, Issue:6 | FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (108.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (7.14%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||